News from mimedx group, inc

Jun 19, 2014, 11:15 ET

MiMedx Expects To File Its First Investigational New Drug Application In July

 MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and...

Jun 19, 2014, 10:45 ET

MiMedx Increases Guidance For Second Quarter And Full Year 2014

 MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and...

Jun 04, 2014, 10:02 ET

MiMedx Board Applauds Dismissal Of Lawsuit Against Chairman & CEO

 The Board of Directors of MiMedx Group, Inc. (NASDAQ: MDXG), announced today that the Board applauds the dismissal of the lawsuit brought...

May 27, 2014, 17:15 ET

MiMedx Increases Lower End Of Guidance For Second Quarter And Full Year 2014

 MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and...

May 20, 2014, 13:48 ET

MiMedx Declines To Participate In NAD Review Proceeding

MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and...

May 12, 2014, 08:30 ET

MiMedx Announces $10 Million Stock Repurchase Program

 MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and...

May 06, 2014, 16:44 ET

Two New MiMedx Scientific Studies Published In Peer-Reviewed Journals

 MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and...

Apr 29, 2014, 16:41 ET

MiMedx Issued Four New U.S. Patents For Placental Tissue Allografts

 MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and...

Apr 25, 2014, 07:30 ET

MiMedx Announces Record Quarterly Results

 MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials...

Apr 23, 2014, 11:12 ET

MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience Demonstrate Clinical And Cost Effectiveness Of EpiFix Allograft For Treatment Of Hard-to-Heal Wounds

EpiFix®, dehydrated human amnion/chorion membrane (dHACM) allografts, were shown to be clinically and cost effective in the treatment of...

Apr 22, 2014, 08:30 ET

MiMedx Files Lawsuit Against Liventa, Medline, And Musculoskeletal Transplant Foundation

 MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and...

Apr 21, 2014, 07:30 ET

MiMedx Sponsors Scott Rigsby, Double-Amputee

 MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and...

Apr 07, 2014, 08:30 ET

MiMedx First Quarter Revenue Exceeded Upper End Of Guidance

 MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials...

Apr 02, 2014, 14:23 ET

MiMedx Group, Inc. Announces Release Date for 2014 First Quarter Results

MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed...

Mar 24, 2014, 08:34 ET

MiMedx Schedules Shareholder Call To Update Progress Of FDA Discussions, Reimbursement Successes And Recent Short-Selling Initiatives

 MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative...

Mar 13, 2014, 14:11 ET

MiMedx EpiFix® Allograft Receives Medicare Coverage From The Final Medicare Contractor

MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and...

Mar 04, 2014, 16:52 ET

MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference

 MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer  of  patent  protected...

Feb 26, 2014, 07:30 ET

MiMedx Announces Record 2013 Results

MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants...

Feb 25, 2014, 20:10 ET

MiMedx Sponsored Osteoarthritis Study Using PURION® Processed Amniotic Tissue Published In Arthritis Research & Therapy

 MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and...

Feb 25, 2014, 19:07 ET

Second MiMedx EpiFix® Randomized Comparative Study Published In International Wound Journal Shows 92.5% Healing Rate Over 12 Weeks

 MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer